Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Plyometric-based Training for Isokinetic Knee Strength and Jump Performance in Cricket Fast Bowlers.

Krishna SA, Alwar TK, Sibeko S, Ranjit S, Sivaraman A.

Int J Sports Med. 2019 Oct;40(11):704-710. doi: 10.1055/a-0970-5564. Epub 2019 Aug 12.

PMID:
31404936
2.

Localized cyclical variations in immunoproteins in the female genital tract and the implications on the design and assessment of mucosal infection and therapies.

Makinde J, Jones C, Bartolf A, Sibeko S, Baden S, Cosgrove C, Shattock RJ.

Am J Reprod Immunol. 2018 Feb;79(2). doi: 10.1111/aji.12801. Epub 2017 Dec 29.

3.

Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.

Naranbhai V, de Assis Rosa D, Werner L, Moodley R, Hong H, Kharsany A, Mlisana K, Sibeko S, Garrett N, Chopera D, Carr WH, Abdool Karim Q, Hill AV, Abdool Karim SS, Altfeld M, Gray CM, Ndung'u T.

BMC Infect Dis. 2016 Jan 25;16:27. doi: 10.1186/s12879-016-1361-1.

4.

Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive.

Ngcapu S, Masson L, Sibeko S, Werner L, McKinnon LR, Mlisana K, Shey M, Samsunder N, Karim SA, Karim QA, Passmore JA.

J Reprod Immunol. 2015 Aug;110:14-21. doi: 10.1016/j.jri.2015.03.007. Epub 2015 Apr 22.

5.

How can we design better vaccines to prevent HIV infection in women?

Rafferty H, Sibeko S, Rowland-Jones S.

Front Microbiol. 2014 Nov 4;5:572. doi: 10.3389/fmicb.2014.00572. eCollection 2014. Review.

6.

HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.

Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool-Karim Q, Abdool-Karim SS.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):55-61. doi: 10.1097/QAI.0000000000000367.

7.

Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial.

Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA.

J Infect Dis. 2014 Jun 15;209(12):1916-20. doi: 10.1093/infdis/jiu026. Epub 2014 Jan 16.

8.

Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.

Matthews LT, Sibeko S, Mansoor LE, Yende-Zuma N, Bangsberg DR, Karim QA.

PLoS One. 2013;8(3):e56400. doi: 10.1371/journal.pone.0056400. Epub 2013 Mar 5.

9.

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.

Etter P, Landovitz R, Sibeko S, Sobieszczyk ME, Riddler SA, Karg C, Tsibris A, Schouten J.

AIDS. 2013 Apr 24;27(7):1119-28. doi: 10.1097/QAD.0b013e32835dc08e. Review.

10.

From the laboratory to clinical trials and back again: lessons learned from HIV prevention trials.

Sibeko S, Makvandi-Nejad S.

Am J Reprod Immunol. 2013 Feb;69 Suppl 1:106-15. doi: 10.1111/aji.12045. Epub 2012 Dec 13. Review.

PMID:
23240676
11.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.

Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.

Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.

PMID:
22914267
12.

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH; CAPRISA004 TRAPS team.

J Infect Dis. 2012 Oct 1;206(7):993-1001. Epub 2012 Jul 24.

13.

The development of CD4 binding site antibodies during HIV-1 infection.

Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M; CHAVI 001 Clinical Team Members, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR.

J Virol. 2012 Jul;86(14):7588-95. doi: 10.1128/JVI.00734-12. Epub 2012 May 9.

14.

CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.

Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, Arney L, Naranbhai V, Treurnicht F, Abrahams MR, Bandawe G, Swanstrom R, Karim QA, Karim SS, Williamson C.

J Infect Dis. 2012 Jul 1;206(1):35-40. doi: 10.1093/infdis/jis305. Epub 2012 May 2.

15.

Contraception and pregnancy in microbicide trials.

Sibeko S, Cohen GM, Moodley J.

Best Pract Res Clin Obstet Gynaecol. 2012 Aug;26(4):473-86. doi: 10.1016/j.bpobgyn.2012.01.005. Epub 2012 Mar 3.

16.

Preservation HIV-1-specific IFN╬│+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.

Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, Sibeko S, Werner L, Abdool Karim Q, Abdool Karim S, Ndung'u T, Altfeld M; CAPRISA004 Trial Group.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9.

17.

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial.

Sibeko S, Baxter C, Yende N, Karim QA, Karim SS.

Obstet Gynecol. 2011 Oct;118(4):895-904. doi: 10.1097/AOG.0b013e31822be512.

18.

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; CAPRISA002 Study Team.

J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9.

19.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

20.

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study.

J Virol. 2011 Apr;85(7):3128-41. doi: 10.1128/JVI.02658-10. Epub 2011 Jan 26.

21.

Strengthening HIV services for pregnant women: an opportunity to reduce maternal mortality rates in Southern Africa/sub-Saharan Africa.

Moodley J, Pattinson RC, Baxter C, Sibeko S, Abdool Karim Q.

BJOG. 2011 Jan;118(2):219-25. doi: 10.1111/j.1471-0528.2010.02726.x. Epub 2010 Sep 24. Review.

22.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

23.

Preventing HIV infection in women: a global health imperative.

Abdool Karim Q, Sibeko S, Baxter C.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S122-9. doi: 10.1086/651483. Review.

Supplemental Content

Loading ...
Support Center